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Abstract: Although achieving blood pressure (BP) control is critical to improve cardiovascular 
prognosis in hypertensive patients, many of them fail to achieve BP goals. The majority of hyper-
tensive patients need more than one antihypertensive agent to attain BP targets. Combination 
therapy is required when monotherapy fails to attain BP objectives and as a ﬁ  rst-line treatment 
in certain situations, such as markedly elevated BP values, when lower targets are required in 
high or very high cardiovascular risk patients. The advantages of combination therapy are well 
documented, with an increased antihypertensive efﬁ  cacy as a result of the simultaneous inhibi-
tion of different mechanisms of action and with a lesser incidence of adverse events, because 
of the possible compensatory responses and the lower doses used. Calcium channel blockers 
are effective drugs in the treatment of hypertension. The efﬁ  cacy of lercanidipine has been 
evaluated in several noncomparative and in comparative studies showing a great efﬁ  cacy with 
a good tolerability. On the other hand, the inhibition of the renin-angiotensin system appears 
to be very beneﬁ  cial in the treatment of patients with hypertension. Enalapril is an effective 
and well tolerated angiotensin converting enzyme inhibitor. Although there are several ﬁ  xed-
combination drugs, the combination lercanidipine plus enalapril appears to be one of the most 
promising therapies in the treatment of hypertension. The aim of this manuscript is to update 
the published data about the efﬁ  cacy and safety of this ﬁ  xed combination.
Keywords: angiotensin converting enzyme inhibitors, calcium channel blockers, combination 
therapy, hypertension, lercanidipine, enalapril
Introduction
Hypertension is a major risk factor for cardiovascular disease. It has been estimated 
that the prevalence of hypertension is about 29.3% in general population and 66.3% 
in elderly (Ong et al 2007; Wang et al 2007). Blood pressure (BP) control is crucial 
to improve cardiovascular prognosis in hypertensive patients (Mancia et al 2007). In 
the US, data from the National Health and Nutrition Examination Survey show that 
only about one third of American hypertensive patients are adequately controlled 
(Cheung et al 2006). Although BP control is still far from optimal, in recent years it 
has markedly improved; as an example, in Spain, BP control has increased from less 
than 20% to the current 40% (Barrios et al 2007a). However, this situation may worsen 
since the most recent recommendations have proposed more strict BP objectives for 
patients at high risk such as those with diabetes, or cardiovascular or renal disease 
in which BP goals should be 130/80 mmHg (Mancia et al 2007). This is clinically 
very relevant, ﬁ  rst, because current evidence shows that nowadays the majority of 
patients daily attended by physicians, regardless they are specialists or general prac-
titioners, are at high or very high risk, and second, because the prevalence of obesity 
and diabetes is likely to grow in the near future, this situation will worsen (Barrios 
et al 2007b; Ryden et al 2007).Vascular Health and Risk Management 2008:4(4) 848
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Figure 1 shows the different BP control rates according 
to different cardiovascular risk conditions provided from 
a recently published survey that enrolled a total of 12,954 
patients with hypertension assisted daily in primary care setting 
(Barrios et al 2007c, d, e). As shown, when cardiovascular risk 
increases, a lower proportion of patients attain BP goals.
It has been reported that most patients with hypertension 
will need at least two antihypertensive drugs to achieve BP 
goals, mainly those patients at higher risk (Motwani 2002; 
Sica 2002; Barrios et al 2007b; Ryden et al 2007). A study 
that analyzed the number of antihypertensive drugs used in 
different clinical trials reported that the median of agents used 
for each patient was 2.8. Despite this, most of them did not 
achieve optimal BP objectives (Lazarus et al 1997; Estacio 
and Schrier 1998; Hansson et al 1998; Bakris et al 2000; 
Brenner et al 2001; Lewis et al 2001; UKPDS 38 2001; ALL-
HAT investigators 2002; Dahlöf et al 2005). Although there 
is a growing awareness about the need of using combinations 
to attain BP goals in most patients, mainly in those at higher 
risk, their use in clinical practice is still far from desirable 
(Figure 2) (Barrios et al 2007c, d, e; Mancia et al 2007).
Rationale of combined therapy
Classically, guidelines for the management of arterial hyperten-
sion recommended “start low, go slow”. This meant that treat-
ment should be initiated at low doses and with slow increases, 
in order to avoid side effects, but assumed incorrectly that in 
most patients with hypertension there was only one underlying 
cause. However, current evidence shows that hypertension is 
caused by interacting multifactorial mechanisms, and this is 
more signiﬁ  cant in high-risk patients (Nesbitt 2007).
As a result, to best treat these patients, it is necessary 
to use combinations of drugs with different mechanisms 
of action. Combined therapy can block counter-regulatory 
mechanisms and potentiate the antihypertensive efﬁ  cacy 
beyond the additive response of each drug alone (McInnes 
2007). Several trials have shown that when the titration of 
medication is very gradual, patients are at risk of present-
ing cardiovascular outcomes before BP goals are obtained, 
especially in those with diabetes or previous cardiovascular 
disease (Hansson et al 1998; UKPDS 1998; Julius et al 2003; 
Nesbitt 2007). The advantages of combination therapy are 
well documented: 1) Increased antihypertensive efﬁ  cacy as 
a result of combining different mechanisms of action; 2) A 
lesser incidence of adverse effects because of the lower doses 
used and the possible compensatory responses; 3) Since ﬁ  xed 
low-dose combinations are available, the treatment simpliﬁ  -
cation may optimize compliance and, secondarily, enhance 
BP control; and 4) Starting treatment with a two-drug com-
bination may allow BP goals to be achieved earlier than with 
only one antihypertensive drug (Mancia et al 2007).
In fact, the JNC-7 report and the European guidelines for 
the management of arterial hypertension recommend a more 
aggressive approach in some patients (Chobanian et al 2003; 
Mancia et al 2007). The JNC-7 report suggests that it should 
be started from the beginning with two antihypertensive drugs 
Figure 1 Blood pressure control rates according to different cardiovascular risk conditions (after Barrios et al 2007c, d, e).
Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease; MetS, metabolic syndrome; CR, coronary risk; DM, diabetes mellitus.
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in those patients with a systolic BP 20 mmHg over BP goal 
and/or 10 mmHg over the diastolic goal (Chobanian et al 
2003). European guidelines are more clear about this issue 
(Mancia et al 2007). Thus, as these recommendations sug-
gest, combination therapy is necessary when monotherapy 
fails to attain BP objectives but also as ﬁ  rst-line treatment in 
some situations, such as high or very high cardiovascular risk, 
when lower BP targets are required, or when BP elevations 
are marked (Mancia et al 2007).
In clinical practice there are numerous ﬁ  xed-dose antihy-
pertensive combination regimens: beta-blockers + hydrochlo-
rothiazide (HCTZ), angiotensin converting enzyme inhibitors 
(ACEi) + HCTZ, angiotensin receptor blockers (ARB) + 
HCTZ, and calcium channel blockers (CCB) + ACEi (Barrios 
and Escobar 2008). One of the most promising combinations 
is lercanidipine (a CCB) + enalapril (an ACEi).
Combining CCB and ACEi: beyond 
blood pressure control
Several randomized clinical trials and studies performed in 
conditions of daily clinical practice have shown that CCBs 
are potent antihypertensive drugs with a good tolerability not 
only in the general hypertensive population but also in high 
risk patients, alone or in combination (Staessen et al 1997; Liu 
et al 1998; Barrios et al 2002, 2006; Nissen et al 2004; Hasebe 
and Kikuchi 2005; Egan 2007; Fogari et al 2007a, b, c; Otero 
2007; Poldermans et al 2007; Sowers et al 2007).
Lercanidipine is a third-generation vasoselective dihydro-
pyridine (DHP) acting through the blockade of the L-type 
calcium channels in cell membranes (Herbette et al 1998; 
Meredith 1999; Epstein 2001; Hair et al 2007). This drug 
has a high lipophilicity, which enables a slower and smooth 
onset and longer duration of action than other classic DHPs 
(Meredith 1999). Lercanidipine is highly selective for vascu-
lar smooth muscle because of the high proportion of L-type 
calcium channels in this tissue (Hair 2007). The efﬁ  cacy of 
lercanidipine has been evaluated in non-comparative and 
in comparative studies with other CCBs and different anti-
hypertensive drugs, showing comparable effects in all the 
cases (Barrios et al 2002, 2006; James et al 2002; Leonetti 
et al 2002; Cherubini et al 2003; Romito et al 2003). The 
effect of lercanidipine has also been successfully evaluated 
in severe or resistant hypertension, elderly subjects, and 
diabetics (Bang et al 2003; Agrawal et al 2006).
Moreover, some studies have suggested that lercanidipine 
may have anti-atherogenic effects beyond BP reductions 
(Soma et al 1998; Rachmani et al 2002; Canavesi et al 2004). 
As an example, lercanidipine reduced by 35% (p  0.001) 
the levels of low-density lipoprotein cholesterol oxidation, 
measured as conjugated diene formation, in a hypertensive 
population with diabetes mellitus (Rachmani et al 2002). 
Other beneﬁ  ts reported with lercanidipine are their reno-
protective effects and favorable effects on lipid proﬁ  le and 
glucose tolerance (Dalla Vestra et al 2004; Robles et al 
2005; Barrios et al 2008). Thus, a study that recruited 203 
chronic renal failure patients (creatinine  1.4 mg/dL for 
males, creatinine  1.2 mg/dL for females, or creatinine 
clearance  70 mL/min) showed that lercanidipine had a 
Figure 2 Use of combined therapy according to different cardiovascular risk conditions (after Barrios et al 2007c, d, e).
Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease; MetS, metabolic syndrome; CR, coronary risk; DM, diabetes mellitus.
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high antihypertensive effect with a good tolerability proﬁ  le 
in patients with renal failure. Moreover, an improvement in 
renal function assessed by creatinine clearance was described 
(Robles et al 2005). On the other hand, lercanidipine has been 
shown to have neutral or favorable effects on lipid proﬁ  le 
and to enhance glucose tolerance and to reduce fasting blood 
glucose and glycosylated haemoglobin in diabetics with 
hypertension (Bang et al 2003; Hair et al 2007). Lercanidip-
ine is a well tolerated drug with a low adverse events rate 
due to its long-lasting and vascular-selective calcium entry-
blocking activity, while sympathetic activation and reﬂ  ex 
tachycardia is not induced (Epstein 2001). As a result, the 
overall adverse events rate is lower than that observed with 
other DHPs (Cherubini et al 2003; Barrios et al 2008).
The renin-angiotensin-aldosterone system (RAAS) plays 
a key role in regulating blood volume and systemic vascular 
resistance. The over-activation of this system, especially 
through the excessive production of its effector peptide, 
angiotensin II, has been related to the genesis and develop-
ment of cardiovascular diseases (Barrios and Escobar 2008). 
Enalapril, an ACEi, is an orally administered prodrug that is 
hydrolyzed to the active form enalaprilat, which reduces the 
plasma levels of angiotensin II (Todd and Heel 1986). This 
reduction of angiotensin II results in peripheral vasodilata-
tion and reduced vascular resistance, leading to a decrease 
in BP values (Hair et al 2007). Enalapril is a dose-dependent 
antihypertensive drug, with the maximum effect occurring 
after 6–8 hours of administration and a total effect duration 
of 24–36 hours (Todd and Heel 1986). Enalapril has shown 
to be an effective antihypertensive agent, with positive effects 
on cardiovascular risk factors and organ damage (Todd and 
Goa 1992; Ravid et al 1998, Hosomi et al 2001; Rosei et al 
2005). Thus, enalapril reduced carotid artery intima-media 
thickness progression, an independent risk factor for cardio-
vascular and cerebrovascular disease (Hosomi et al 2001). 
Moreover, in a randomized, double-blind, 6-year trial in 
patients with diabetes and normoalbuminuria at baseline, 
enalapril reduced the development of microalbuminuria 
(Ravid et al 1998).
The combination of CCB and ACEi is especially effec-
tive due to their complementary mechanisms that enhance 
the antihypertensive efﬁ  cacy with a low side effects rate 
(McInnes 2007). CCBs are potent vasodilators that induce 
reﬂ  ex activation of the sympathetic system and RAAS. As 
a result, the use of an ACEi may buffer this excessive acti-
vation. Moreover, since CCBs promote a negative sodium 
balance and an increase of angiotensin II levels, this may 
reinforce the antihypertensive effect of ACEis (Gojanovic 
et al 2008). On the other hand, the concomitance of both 
treatments may reduce the presence of adverse events, 
mainly the peripheral oedema (Messerli 2002). Mechanisti-
cally, the development of lower extremity oedema during 
calcium entry blockade is due to an increase in intracapil-
lary pressure, as a consequence of a selective diminution of 
the precapillary arteriolar tone. Interestingly, ACEis reduce 
the lower extremity oedema caused by CCBs, most likely 
because of their ability to dilate both the arterial vascular 
bed and the venous capacitance vessels (Weir et al 2001; 
Gojanovic et al 2008).
Fixed combination lercanidipine 
plus enalapril: current evidence
Several trials have demonstrated the beneﬁ  ts of the ﬁ  xed 
combination of lercanidipine and enalapril (Recordati 2004a, b; 
Agrawal et al 2006; Puig et al 2007). In a trial performed in 
hypertensive patients who were nonresponders to lercani-
dipine, after 12 weeks of treatment with ﬁ  xed combination 
lercanidipine plus enalapril, a signiﬁ  cantly greater proportion 
of patients with this combination normalized their BP com-
pared with patients treated with lercanidipine in monotherapy 
(22% vs 12%, p = 0.012) (Recordati 2004a). Similarly, in 
another study developed in patients with hypertension who 
were nonresponders to enalapril, after 12 weeks of treatment 
with this ﬁ  xed combination, there was a trend to a better BP 
control in the population treated with the ﬁ  xed combination 
compared with enalapril in monotherapy (24% vs 17%, 
p = NS) (Recordati 2004b).
More recently, a double-blind, placebo-controlled, four-
way balanced design crossover study included hypertensive 
patients aged 60–85 years with mean ofﬁ  ce-measured sitting 
systolic BP 160–179 mmHg and daytime ambulatory systolic 
BP 135 mmHg (Puig et al 2007). After a 2-week run-in 
period, during which previous medications were discontin-
ued, each patient were randomly allocated to lercanidipine 
10 mg, enalapril 20 mg, lercanidipine 10 mg plus enalapril 
20 mg, or placebo. Of the 75 patients randomized, 62 com-
pleted the study. At study end, ofﬁ  ce BP was measured and 
a 24-hour ambulatory BP monitoring was performed. The 
administration of placebo, lercanidipine, enalapril, and ler-
canidipine plus enalapril was associated with a mean 24-hour 
systolic BP of 144, 137, 133, and 127 mmHg, respectively. 
All active treatments signiﬁ  cantly reduced the mean 24-hour 
BP compared with placebo, but the combination lercanidipine 
plus enalapril was signiﬁ  cantly more effective than the active 
components taken in monotherapy. Similarly, ofﬁ  ce systolic 
BP was signiﬁ  cantly more reduced with the combination Vascular Health and Risk Management 2008:4(4) 851
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than with the monotherapies. A higher proportion of patients 
treated with the combination lercanidipine plus enalapril 
achieved BP goals compared with lercanidipine and enalapril 
alone (45% vs 18% vs 19%, respectively).
The combination lercanidipine plus enalapril has been 
shown to be effective not only in the general hypertensive 
population but also in high-risk patients, such as those 
with diabetes. A controlled clinical trial investigated the 
efﬁ  cacy of lercanidipine vs HCTZ as add-on therapy in dia-
betic patients with uncontrolled hypertension on enalapril 
monotherapy (Agrawal et al 2006). A total of 174 patients 
with well-controlled diabetes and mild to moderate hyper-
tension were included in a 2-week placebo run-in followed 
by 4 weeks on enalapril 20 mg. Subsequently, 135 non-
responders were randomized to 20 weeks of double-blind 
add-on therapy to enalapril with either lercanidipine 10 
mg (n = 69) or HCTZ 12.5 mg (n = 66). BP response rates 
reached 69.6% on enalapril plus lercanidipine compared 
with 53.6% on enalapril plus HCTZ (p = NS) and BP 
control was attained in 30.4% of patients on lercanidipine 
add-on and in 23.2% of those randomized to HCTZ add-on 
(p = NS). Figure 3 summarizes BP control rates achieved 
by the combination lercanidipine plus enalapril in different 
clinical trials.
The combination lercanidipine plus enalapril was well 
tolerated in all clinical trials, with a similar rate of side effects 
than the drugs in monotherapy (Recordati 2004a b; Agrawal 
et al 2006; Puig et al 2007). Although infrequent, the most 
prevalent adverse events related to the use of the combina-
tion lercanidipine plus enalapril were cough, dizziness, and 
vertigo. Interestingly, no clinically signiﬁ  cant differences in 
heart rate were observed between groups and 24-hour heart 
rate remained stable under all treatments (Puig et al 2007). 
The absence of negative effects of the combination on lipid 
and glucose metabolism appears an added advantage in the 
treatment of hypertensive population (Hair et al 2007).
Conclusions and future perspectives
Most patients with hypertension often require more than 
one drug to achieve BP goals. The most recent European 
guidelines clearly establish that combination therapy is 
recommended as ﬁ  rst-line therapy in certain situations, such 
as marked BP elevations, high or very high-risk patients, or 
when BP targets are lower (Mancia et al 2007). Clinical trials 
have shown that the combination lercanidipine plus enalapril 
is an effective and well-tolerated ﬁ  xed-dose antihypertensive 
combination. As expected, it provides greater antihyperten-
sive efﬁ  cacy than either component taken as monotherapy. 
Figure 3 Blood pressure control rates achieved by the combination lercanidipine plus enalapril in different clinical trials (after Recordati 2004a, b; Agrawal et al 2006; 
Puig et al 2007). *p = NS; +p = 0.01.
Abbreviations: L, lercanidipine; E, enalapril; HTZ, hydrochlorothiazide.
0
10
20
30
40
50
60
30.4%*
23.2%
45%+
19% 18%
22%+
12%
24%*
17%
L+E HTZ+E L+E E L L+E L L+E E
Agrawal et al Puig et al CPL1-0018 CPL1-0019Vascular Health and Risk Management 2008:4(4) 852
Barrios et al
But to date studies assessing the effects of lercanidipine 
plus enalapril in reversing left ventricular hypertrophy or 
progression of renal disease, or improving clinical outcomes 
in hypertensive patients are still warranted .
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